4.5 Article

NDGA reduces secondary damage after spinal cord injury in rats via anti-inflammatory effects

期刊

BRAIN RESEARCH
卷 1516, 期 -, 页码 83-92

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.brainres.2013.04.016

关键词

NDGA; Neuron protection; Secondary damage; Rat; Spinal cord injury; Inflammation

资金

  1. Chinese National Natural Science Foundation [30970739]
  2. Jilin Province Science Foundation [20090726, 201115116]

向作者/读者索取更多资源

After spinal cord injury (SCI), a series of complex pathophysiological processes follows the initial injury. Because inflammation plays a key role in this secondary pathology damage, anti-inflammatory drug treatment may reduce secondary damage and protect neurons after SCI. Though nordihydroguaiaretic acid (NDGA) can inhibit inflammatory responses, its potential roles in neuroprotection and anti- inflammation in an SCI model have not been studied. In this study, we investigated the anti-inflammatory effects of NDGA in SCI. First, histopathological alterations were evaluated with hematoxylin/eosin (HE) and Nissl staining, showing an increased number of neurons after NDGA administration. Additionally, the extent of secondary damage was assessed by TUNEL assay and measurement of astrocyte proliferation. The data showed that the numbers of apoptotic cells and the proliferative extent of astrocytes were significantly decreased by the use of NDGA. The anti-inflammatory effect of NDGA was evaluated by measuring myeloperoxidase (MPO) levels as an indicator of neutrophil activity, macrophage/microglia numbers, and expression of inflammatory cytokines including IL-1 beta and TNF-alpha. NDGA treatment significantly decreased the MPO level and the number of macrophages/microglia. In addition, NDGA also suppressed the expression of IL-1 beta and TNF-alpha after SCI. These data suggest that anti-inflammatory action by NDGA can reduce secondary damage after SCI (c) 2013 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据